Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05983770 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

A Phase 2 study, sponsored by Eledon Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
127
Enrollment target

NCT05983770: Completed Phase 2 study, sponsored by Eledon Pharmaceuticals.

NCT05983770 is a Phase 2 study that has completed, run by Eledon Pharmaceuticals. The registered enrollment target is 127 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05983770, a Phase 2 study, has completed, sponsored by Eledon Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
127 participants
Enrollment target

Study Summary

This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.

Primary Outcome

Estimated Glomerular Filtration Rate (eGFR) at 12 months post-transplant

Interventions

  • DRUG Tacrolimus
  • DRUG AT-1501

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2023-08-30
Est. Completion 2025-09-25
Phase Phase 2
Eledon Pharmaceuticals

2 total trials

What the finished NCT05983770 record still lists

NCT05983770 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which Tacrolimus is the first listed.

NCT05983770 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05983770 about?

NCT05983770 is a clinical study titled "Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation". This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.

What is the current status of trial NCT05983770?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2023-08-30. Estimated completion is 2025-09-25.

What interventions are being tested in trial NCT05983770?

The interventions under investigation include: Tacrolimus (DRUG), AT-1501 (DRUG).

Who is sponsoring clinical trial NCT05983770?

This trial is sponsored by Eledon Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05983770's enrollment target sits among peer trials

127 555th of 2000 higher than 1,445 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03017820 · 127 participants · Phase 1

    A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

  • NCT03609580 · 127 participants · Phase 1

    Post-operative Urinary Retention (POUR) Following Thoracic Surgery

  • NCT06285643 · 127 participants · Phase 2

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

  • NCT06809400 · 127 participants · Phase 1

    A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05983770, the US trial registry maintained by the National Library of Medicine. NCT05983770 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.